Joachim Struck

This inventor holds 65 USPTO granted patents and 30 published patent applications and 42 EPO patents, primarily in Biomarker Diagnostics (CPC class G01N). Top assignees: B.r.a.h.m.s Gmbh, B.r.a.h.m.s Aktiengesellschaft, B.r.a.h.m.s. Diagnostica Gmbh. Active years: 1997-2023.

USPTO Granted Patents = 65 (Patent Applications = 30)

% Patents Active = 72.3

EPO Patents = 42 (Patent Applications = 42)

Average Co-Inventor Count = 2.6

ph-index = 12

Forward Citations = 412(Granted Patents)

Forward Citations (Not Self Cited) = 347(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

B.r.a.h.m.s Aktiengesellschaft

patents

3 out of 11

B.r.a.h.m.s. Diagnostica Gmbh

patents

4. 2 out of 3,067

The General Hospital Corporation

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

Areas of Expertise:

Procalcitonin

Heart Failure

Acute Coronary Syndrome

Proadrenomedullin

Diagnostic Biomarkers

Vasoactive Hormones

Immunoassays

Risk Stratification

Chronic Kidney Disease

Antibiotic Treatment

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11835531 - Procalcitonin for the prognosis of adverse events (2023-12-05),

2. 11402393 - Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints (2022-08-02),

3. 11241395 - Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease (2022-02-08),

4. 10954298 - Method of obtaining a binder to prepro-vasopressin or fragments thereof (2021-03-23),

5. 10718783 - Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II (2020-07-21),

6. 10456364 - Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease (2019-10-29),

7. 10254289 - In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient (2019-04-09),

8. 10048280 - Immunoassay for the detection of procalcitonin (2018-08-14),

9. 10024872 - Augurin immunoassay (2018-07-17),

10. 9952229 - Arginine vasopressin pro-hormone as predictive biomarker for diabetes (2018-04-24),

11. 9885709 - Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination (2018-02-06),

12. 9829494 - Methods of treatment using ADM antibodies (2017-11-28),

13. 9810699 - Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin (2017-11-07),

14. 9753039 - Prognosis of adverse events in patients with suspected chronic heart failure (2017-09-05),

15. 9726675 - Diagnosis and risk stratification by determining the marker CT-proADM (2017-08-08),

Title: Joachim Struck - Innovative Inventor from Berlin

Introduction: Joachim Struck is a renowned inventor based in Berlin, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Joachim Struck holds several patents in the areas of renewable energy, sustainable transportation, and advanced materials, showcasing his commitment to creating a more sustainable future.

Career Highlights: With over two decades of experience in research and development, Joachim Struck has led numerous successful projects that have resulted in cutting-edge innovations with real-world applications.

Collaborations: Throughout his career, Joachim Struck has collaborated with leading universities, research institutions, and tech companies, fostering a culture of innovation and knowledge sharing in the industry.

Conclusion: Joachim Struck's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and researchers worldwide.